Xenetic Biosciences reports FY2024 net loss of ~$4.0M, cash $6.2M, advances DNase program

Xenetic Biosciences, Inc.

Net loss for FY2024 ~$4.0M; R&D expenses $3.3M (down 5.9% YoY), G&A $3.4M (down 4.1%).
Royalty payments from Takeda sublicense ~$2.5M, flat YoY; cash balance $6.2M at year-end.
Entered Clinical Trial Services Agreement with PeriNess for DNase I studies in pancreatic, colorectal, and solid tumors.
Extended collaborations with University of Virginia and Scripps Research through 2025.
Progressing DNase I development program toward IND and first-in-human study for pancreatic carcinoma.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.